LFVN

LifeVantage Corporation (NASDAQ:LFVN) is included among the 12 Best Micro-Cap Dividend Stocks to Buy Now. On May 7, Lake Street downgraded LifeVantage Corporation (NASDAQ:LFVN) to Hold from Buy and set a $5 price target after the company reported weaker-than-expected Q3 results. The analyst said management kept its prior FY26 guidance framework in place but now expects results to land near the low end of the range. The firm also lowered its estimates below the company’s updated outlook. The analyst noted that while the stock valuation “remains inexpensive,” revenue headwinds were expected to continue for at least the next two quarters, which could limit upside potential. During the company’s fiscal Q3 2026 earnings call, Interim CEO & Director Michael Beindorff said LifeVantage had launched the VIP bonus program, calling it the company’s first 12-month volume growth incentive initiative for consultants. He explained that the program was designed to reward sales growth while also helping identify and elevate consultants to strengthen leadership within the organization. Beindorff also said the company was investing heavily in its e-commerce platform. He noted that the rollout of Shopify, along with a fully upgraded back-office system, was expected to improve the online experience for both customers and consultants. He added that the Shopify launch was planned for later this year. CFO Carl Aure said LifeVantage generated $43.7 million in net revenue during fiscal Q3 2026, down 25.2% from a year earlier. He said the decline was mainly tied to weaker sales of the MindBody GLP-1 System, though contributions from LoveBiome sales helped offset part of the drop. LifeVantage Corporation (NASDAQ:LFVN) is an activation company engaged in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, weight management products, pre- and probiotics, skin and hair care products, and nootropics. While we acknowledge the potential of LFVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 14 Best Dividend Stocks to Buy for Steady Growth and 10 Best Robin...

Performance was significantly impacted by a decline in sales of the MINDBODY GLP-1 system, which management attributed to intense competitive dynamics within the GLP-1 market. The company is undergoing a major leadership transition with Michael Beindorff serving as Interim CEO following the retirement of Steve Fife, until Terrence Moorhead assumes the role in August. Management is prioritizing a 'foundational approach' to consultant growth, moving away from temporary sales spikes toward sustainable leadership development and authentic product advocacy. A significant multi-period investment in technology is underway, centered on migrating to Shopify and revamping back-office systems to modernize the end-to-end e-commerce experience. The acquisition of LoveBiome in October 2025 served as a strategic offset to revenue declines, integrating gut health as a core pillar of the product portfolio. Operational focus is shifting toward the 'VIP bonus' program, a 12-month incentive designed to identify and reward consultants demonstrating long-term leadership behaviors. Despite revenue contraction, the company maintains a debt-free balance sheet and cash reserves, providing the flexibility needed to fund strategic pivots and technology upgrades. Fiscal 2026 guidance has been narrowed to the lower end of previous ranges for revenue, adjusted EBITDA, and adjusted EPS due to current business trends and market competition. The Shopify platform rollout is expected to begin later this year with a staggered international approach, targeting full implementation starting in Q1 of the next fiscal year. Management anticipates a major 'hero product' launch at the annual convention in October 2024, following their typical 18-to-24-month innovation cadence. Full-year fiscal 2026 commissions and incentive expenses are projected to be approximately 42.5% of revenue, reflecting changes in customer mix and promotional timing. The company expects a full-year effective tax rate between 18% and 20% for fiscal 2026. Gross profit margin compressed to 79% from 81%, driven by increased shipping costs, warehouse expenses, and inventory obsolescence related to the MINDBODY system. The Board approved a new $60 million share repurchase authorization in January, with $59 million remaining as of the end of the third quarter. A quarterly cash dividend of $0.05 per share was announced, representing an...

SALT LAKE CITY, May 06, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2026. Third Quarter Fiscal 2026 Summary*: Revenue was $43.7 million, a decrease of 25.2% from the prior year period; Revenue in the Americas decreased 28.9%, and revenue in Asia/Pacific & Europe decreased 7.7%; Net income per diluted share was $0.11, versus $0.26 per diluted share a year ago; Adjusted earnings per diluted share was $0.12, compared to $0.26 a year ago; and Adjusted EBITDA was $3.2 million compared to $6.4 million a year ago. * All comparisons are on a year over year basis and compare the third quarter of fiscal 2026 to the third quarter of fiscal 2025, unless otherwise noted. "Third quarter results were softer than we anticipated as lower sales of our MindBody GLP-1 System® were only partially offset by the addition of LoveBiome," said Michael Beindorff, Interim CEO of LifeVantage. "Despite top-line headwinds, we remained focused on managing expenses and allocating capital, enabling us to continue repurchasing shares while maintaining a strong balance sheet and cash position. That said, we are not satisfied with our performance and are laser focused on making the changes necessary to improve results going forward. With our science-backed approach to nutrigenomics, diversified product portfolio, passionate consultant community, and strong financial foundation, LifeVantage is in a compelling position in the rapidly expanding health and wellness market with significant growth potential ahead, and we intend to realize that potential." Third Quarter Fiscal 2026 Results For the third quarter ended March 31, 2026, the Company reported revenue of $43.7 million, a 25.2% decrease compared to revenue of $58.4 million in the third quarter of fiscal 2025. Revenue in the Americas region for the third quarter of fiscal 2026 decreased 28.9% primarily due to declines in sales of the MindBody GLP-1 System®, partially offset by sales of LoveBiome, which the Company acquired in October 2025. Revenue in the Asia/Pacific & Europe region decreased 7.7%; on a constant currency basis, revenue in the Asia/Pacific & Europe region decreased approximately 8.9%. Gross profit for the third...

Image source: The Motley Fool. Wednesday, May 6, 2026 at 4:30 p.m. ET Interim Chief Executive Officer — Michael Beindorff Chief Financial Officer — Carl Aure Chief Sales Officer — Kristen Cunningham Need a quote from a Motley Fool analyst? Email [email protected] Michael Beindorff, Interim Chief Executive Officer; Carl Aure, Chief Financial Officer; and Kristen Cunningham, Chief Sales Officer. By now, everyone should have access to the earnings release, which went out this afternoon at approximately 4: 05 p.m. Eastern Time. If you have not received the release, it is available on the Investor Relations portion of LifeVantage Corporation's website at lifevantage.com. This call is being webcast, and a replay will be available on the company's website as well. Before we begin, we would like to remind everyone that our prepared remarks contain forward-looking statements, and management may make additional forward-looking statements in response to your questions. These statements do not guarantee future performance, and therefore, undue reliance should not be placed upon them. These statements are based on current expectations of the company's management and involve inherent risks and uncertainties, including those identified in the Risk Factors section of LifeVantage Corporation's most recently filed Forms 10-K and 10-Q. Please note that during today's call, we will discuss non-GAAP financial measures, including results on an adjusted basis. Management believes these financial measures can facilitate a more complete analysis and greater transparency into LifeVantage Corporation's ongoing results of operations, particularly when comparing underlying operating results from period to period. We have included a reconciliation of these non-GAAP measures with today's release. This call also contains time-sensitive information that is accurate only as of the date of the live broadcast, 05/06/2026. LifeVantage Corporation assumes no obligation to update any forward-looking projections that may be made in today's release or call. Now I will turn the call over to Michael Beindorff, Interim CEO of LifeVantage Corporation. Michael Beindorff: Thank you, Reed. Good afternoon, and thank you all for joining us today. For those of you I have not had the opportunity to meet, let me briefly introduce myself. I have had the privilege of serving on the LifeVantage Corporation board of dir...

Lifevantage (LFVN) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.26 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -25.00%. A quarter ago, it was expected that this dietary supplements and skin care products company would post earnings of $0.22 per share when it actually produced earnings of $0.15, delivering a surprise of -31.82%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Lifevantage, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $43.72 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 8.58%. This compares to year-ago revenues of $58.44 million. The company has not been able to beat consensus revenue estimates over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Lifevantage shares have lost about 10.9% since the beginning of the year versus the S&P 500's gain of 6%. While Lifevantage has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Lifevantage was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the comple...

Revenue fell sharply: LifeVantage reported Q3 net revenue of $43.7 million, down 25.2% year‑over‑year largely due to weaker MindBody GLP‑1 System sales and fewer active accounts, with adjusted EBITDA declining to $3.2 million (7.3% of revenue) from $6.4 million. Leadership and strategic shifts: The board appointed Terrence Moorehead as incoming CEO (joining in August) while interim CEO Michael Beindorff highlighted investments in e‑commerce (Shopify migration), consultant tools, and a new 12‑month VIP bonus to drive field engagement and product cadence. Solid liquidity and capital moves but cautious outlook: The company ended the quarter with $12.5 million cash, no debt, repurchased shares under a large buyback program (about $59 million remaining under authorization), raised its quarterly dividend 11% to $0.05, and now expects fiscal 2026 results near the lower end of prior guidance amid GLP‑1 competitive pressures. Interested in Lifevantage Corporation? Here are five stocks we like better. GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends Lifevantage (NASDAQ:LFVN) reported fiscal third-quarter 2026 results that reflected a sharp year-over-year revenue decline, as management pointed to weaker demand for its MindBody GLP-1 System and fewer active accounts. On the call, the company also highlighted a leadership transition, ongoing technology investments, and new consultant incentive programs aimed at improving long-term growth. Interim CEO Michael Beindorff, a long-time board member who has served since 2012, opened the call by recognizing the retirement of former President and CEO Steve Fife, who stepped down April 30. Beindorff said Fife’s tenure was “transformational,” citing modernization efforts, improved financial positioning, and the groundwork laid for the company’s future. → The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches Beindorff also reiterated the company’s focus on its portfolio, including the Protandim family and newer offerings such as TrueScience Liquid Collagen, the MindBody GLP-1 System, and its Gut Activator product P84, which came with the October 2025 LoveBiome acquisition. He emphasized the role of the company’s consultant community and described the recent Momentum Academy event in Las Vegas as a showcase of field engagement. At the event, the company announced what Beindorff described as its “firs...

LEHI, Utah (AP) — LEHI, Utah (AP) — Lifevantage Corp. (LFVN) on Wednesday reported net income of $1.4 million in its fiscal third quarter. The Lehi, Utah-based company said it had profit of 11 cents per share. Earnings, adjusted for non-recurring costs, came to 12 cents per share. The dietary supplements and skin care products company posted revenue of $43.7 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on LFVN at https://www.zacks.com/ap/LFVN

Increases Quarterly Cash Dividend by 11% to $0.050 SALT LAKE CITY, May 06, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company’s Board of Directors has approved a quarterly cash dividend of $0.050 per share of common stock, which will be paid June 15, 2026 to all stockholders of record at the close of business on June 1, 2026. About LifeVantage Corporation LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, the MindBody GLP-1 System®, the newest comprehensive gut activator from LoveBiome P84, the Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic and hydration energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com. Cautionary Note Regarding Forward Looking Statements This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "will," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates," "look forward to," "goal," “may be,” and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The declaration and/or payment of a dividend during any quarter provides no assurance as to future dividends, and the timing and amount of future dividends, if any, could vary significantly in comparison...

SALT LAKE CITY, April 22, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its third quarter ended March 31, 2026, after the stock market closes on Wednesday, May 6, 2026. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day. Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available approximately two hours after the call concludes and will be available through Wednesday, May 20, 2026, by dialing (844) 512-2921 from the U.S. and entering confirmation code 13759699, or (412) 317-6671 from international locations, and entering confirmation code 13759699. There will also be a simultaneous, live webcast available on the Investor Relations section of the Company's web site at https://lifevantage.gcs-web.com/events-and-presentations or directly at https://viavid.webcasts.com/starthere.jsp?ei=1758157&tp_key=76e0807216. The webcast will be archived for approximately 30 days. About LifeVantage Corporation LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, MindBody GLP-1 System™, and the comprehensive gut activator, P84, and activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com. Investor Relations Contact: Reed Anderson, ICR (646) 277-1260 reed.a...

Lifevantage (LFVN) came out with quarterly earnings of $0.15 per share, missing the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.22 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -31.82%. A quarter ago, it was expected that this dietary supplements and skin care products company would post earnings of $0.17 per share when it actually produced earnings of $0.18, delivering a surprise of +5.88%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Lifevantage, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $48.93 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 10.62%. This compares to year-ago revenues of $67.76 million. The company has not been able to beat consensus revenue estimates over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Lifevantage shares have lost about 13% since the beginning of the year versus the S&P 500's gain of 1.1%. While Lifevantage has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Lifevantage was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the com...

Revenue fell sharply to $48.9 million, down 27.8% year‑over‑year as MindBody GLP‑1 sales dropped by about $16.2 million; the company also took a $2.4 million one‑time inventory obsolescence reserve, pushing gross margin down to 74% (78.8% adjusted). LoveBiome acquisition showing early traction — the new portfolio contributed $4.1 million in Q2 and LifeVantage launched AXIO X and PhytoPower B while highlighting its P84/Healthy Edge Stack as key enrollment products. Management approved a $60 million share repurchase program, declared a quarterly dividend of $0.045 per share, updated fiscal‑2026 guidance (revenue $185–200M, adjusted EBITDA $15–19M, adjusted EPS $0.60–0.80), and said the company is debt‑free with $10.2 million cash; CEO Steve Fife plans to retire in April 2026. Interested in Lifevantage Corporation? Here are five stocks we like better. GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends LifeVantage (NASDAQ:LFVN) reported fiscal second-quarter 2026 results that reflected a sharp year-over-year decline in revenue and earnings as the company cycled the prior-year launch of its MindBody GLP-1 System and faced intensifying competition in the broader GLP-1 category. Management also highlighted early momentum from the LoveBiome acquisition, new product launches, and a major new share repurchase authorization. Chief Executive Officer Steve Fife said the “primary driver” of the quarter’s revenue decline was the shift in competitive dynamics since the October launch of MindBody GLP-1. Fife pointed to pharmaceutical GLP-1 drugs becoming “more accessible and affordable,” increasingly covered by insurance, and available in new formats, including pills. He said those changes “dramatically impacted” LifeVantage’s GLP-1 sales. → AMD’s Post-Earnings Dip Looks Like the Buying Window Bulls Wanted As part of its response, the company recorded a reserve against a portion of its GLP-1 inventory. CFO Carl Aure said gross margin was impacted by a $2.4 million one-time allowance for inventory obsolescence tied to MindBody inventory. In Q&A, Aure said the company built inventory following an exceptionally strong initial launch—selling through initial stock in about three weeks—and later took a “conservative approach” to reserve inventory as demand “settled in” and visibility into seasonality improved. He noted the product has a two-year shelf life and the com...